Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles

Seminars in Arthritis and Rheumatism

Volumn 26, Issue 6 SUPPL. 1, 1997, Pages 28-33

  Fenner, H ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Assay systems; Cyclooxygenase; NSAIDs; Toxicity

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; THROMBOXANE B2;

ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0030969888     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(97)80050-9     Document Type: Article

References (14)

1. Henry D. Lim L.L.-Y. García Rodríguez L.A. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborativemeta-analysis Br Med J 312 1996 1563 1566
2. Meade E.A. Smith W.L. DeWitt D.I. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs J Biol Chem 268 1993 6610 6614
3. Mitchell J.A. Akarasereenont P. Thiemermann C. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci U S A 90 1993 11693 11697
4. Engelhardt G. Bögel R. Schnitzer Chr. Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings Biochem Pharmacol 51 1996 21 28
5. Churchill L. Graham A.G. Shih C.-K. Selective inhibition of human cyclooxygenase-2 by meloxicam Inflammopharmacology 4 1996 125 135
6. Laneuville O. Breuer D.K. DeWitt D.L. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal antiinflammatory drugs J Pharmacol Exp Ther 271 1994 927 934
7. Patrignani P. Panara M.R. Greco A. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J Pharmacol Exp Ther 271 1994 1705 1712
8. Cipollone C. Ganci A. Panara M.R. Effects of nabumetone on prostanoid biosynthesis in man Clin Pharmacol Ther 58 1995 335 341
9. Stichtenoth D.O. Wagner B. Frölich J.C. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers J Invest Med 45 1997 44 49
10. Brideau C. Karman S. Liu S. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors Inflamm Res 45 1996 68 74
11. Glaser K.B. Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (Lodine) Inflammopharmacology 3 1995 335 345
12. Young J.M. Panah S. Satchawatcharaphong C. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysacchaxide stimulation of thromboxane B2production Inflamm Res 45 1996 246 253
13. Pairet M. Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacokinetic profile in vivo of NSAIDs Vane J. Bolting J. Bolting R. Improved Non-steroid Anti-inflammatory Drugs-COX-2 Enzyme Inhibitors 1996 Kluwer Academic Publishing Dordrecht, Boston, London 103 119
14. Distel M. Mueller C. Bluhmki E. Fries J. Safety of meloxicam: a global analysis of clinical trials Br J Rheumatol 35 Suppl 1 1996 68 77